Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. N-(4-methoxyphenyl)-4-menthone-3-carboxamide
2. N-(4-methoxyphenyl)-p-menthone-3-carboxamide
3. Ws 12 Compound
4. Ws-12
5. Ws-12 Compound
6. Ws12 Compound
1. Ws-12
2. Ws 12
3. (1r,2s,5r)-n-(4-methoxyphenyl)-5-methyl-2-(propan-2-yl)cyclohexane-1-carboxamide
4. Fema No. 4681
5. N-(4-methoxyphenyl)-p-menthanecarboxamide
6. Cyclohexanecarboxamide, N-(4-methoxyphenyl)-5-methyl-2-(1-methylethyl)-, (1r,2s,5r)-
7. (1r,2s,5r)-n-(4-methoxyphenyl)-5-methyl-2-(1-methylethyl)cyclohexanecarboxamide
8. N-(4-methoxyphenyl)-p-menthane-carboxamide
9. (1r,2s,5r)-methoxyphenyl)-5-methyl-2-propan-n-(4-2-ylcyclohexane-1-carboxamide
10. N-(4-methoxyphenyl)-5-methyl-2-(1-methylethyl)cyclohexanecarboxamide, (1r,2s,5r)-
11. 68489-09-8
12. Acoltremon
13. Cyclohexanecarboxamide,n-(4-methoxyphenyl)-5-methyl-2-(1-methylethyl)-, (1r,2s,5r)-
14. 1l7bvt4z4z
15. (1r,2s,5r)-n-(4-methoxyphenyl)-5-methyl-2-propan-2-ylcyclohexane-1-carboxamide
16. (1r,2s,5r)-2-isopropyl-n-(4-methoxyphenyl)-5-methylcyclohexane-1-carboxamide
17. Chembl2441929
18. Avx-012
19. [1r,2s,5r]-n-(4-methoxyphenyl)-p-menthanecarboxamide
20. Ws12
21. Hnsgvpaaxjjopq-xokhgstosa-n
22. Acoltremon [inn]
23. Unii-1l7bvt4z4z
24. Gtpl4343
25. Schembl2575067
26. Dtxsid10460636
27. Glxc-22261
28. Tca48909
29. Bdbm50442649
30. Akos024457397
31. Ws 12 Is Known As A Trpm8 Agonist.
32. Da-59157
33. Kxs
34. Hy-108449
35. Cs-0028711
36. E77039
37. Q27089230
38. N-(4-methoxyphenyl)-5-methyl-2- (1-methylethyl)cyclohexanecarboxamide, (1r,2s,5r)-
39. 847565-93-9
40. Cyclohexanecarboxamide, N-(4-methoxyphenyl)-5-methyl-2-(1-methylethyl)-, [1r-(1alpha,2beta,5alpha)]-
| Molecular Weight | 289.4 g/mol |
|---|---|
| Molecular Formula | C18H27NO2 |
| XLogP3 | 4.6 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 4 |
| Exact Mass | Da |
| Monoisotopic Mass | Da |
| Topological Polar Surface Area | 38.3 |
| Heavy Atom Count | 21 |
| Formal Charge | 0 |
| Complexity | 334 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
Tryptyr (acoltremon) is a TRPM8 thermoreceptor agonist indicated for the treatment of the signs and symptoms of dry eye disease.
Lead Product(s): Acoltremon
Therapeutic Area: Ophthalmology Brand Name: Tryptyr
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 28, 2025
Lead Product(s) : Acoltremon
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alcon Wins FDA Approval for TRYPTYR for Signs and Symptoms of Dry Eye Disease
Details : Tryptyr (acoltremon) is a TRPM8 thermoreceptor agonist indicated for the treatment of the signs and symptoms of dry eye disease.
Product Name : Tryptyr
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 28, 2025
Details:
Both formulations of AR-15512 were safe and well-tolerated. Ninety five percent of adverse events were mild with less than 3 percent of subjects discontinued due to adverse events.
Lead Product(s): Acoltremon
Therapeutic Area: Ophthalmology Brand Name: AVX012
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 15, 2021
Lead Product(s) : Acoltremon
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Both formulations of AR-15512 were safe and well-tolerated. Ninety five percent of adverse events were mild with less than 3 percent of subjects discontinued due to adverse events.
Product Name : AVX012
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 15, 2021
Details:
The COMET-1 trial is a randomized, double-masked, vehicle-controlled trial evaluating the efficacy and safety of AR-15512 (TRPM8 agonist) in patients with dry eye disease. AR-15512 is a TRPM8 agonist for the treatment of patients with dry eye disease.
Lead Product(s): Acoltremon
Therapeutic Area: Ophthalmology Brand Name: AVX012
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 29, 2020
Lead Product(s) : Acoltremon
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The COMET-1 trial is a randomized, double-masked, vehicle-controlled trial evaluating the efficacy and safety of AR-15512 (TRPM8 agonist) in patients with dry eye disease. AR-15512 is a TRPM8 agonist for the treatment of patients with dry eye disease.
Product Name : AVX012
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 29, 2020
Details:
The active ingredient in AR-15512 is a potent and selective agonist of the TRPM8 cold thermoreceptor ion channel that regulates tear production and blink rate. The acceptance of the IND for AR-15512 marks the first clinical-stage dry eye product candidate for Aerie.
Lead Product(s): Acoltremon
Therapeutic Area: Ophthalmology Brand Name: AVX012
Study Phase: Phase I/ Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 29, 2020
Lead Product(s) : Acoltremon
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The active ingredient in AR-15512 is a potent and selective agonist of the TRPM8 cold thermoreceptor ion channel that regulates tear production and blink rate. The acceptance of the IND for AR-15512 marks the first clinical-stage dry eye product candidat...
Product Name : AVX012
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
Regulatory Info : RX
Registration Country : USA
Brand Name : TRYPTYR
Dosage Form : SOLUTION/DROPS;OPHTHALMIC
Dosage Strength : 0.003%
Packaging :
Approval Date : 2025-05-28
Application Number : 217370
Regulatory Info : RX
Registration Country : USA
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
RLD : Yes
TE Code :
Brand Name : TRYPTYR
Dosage Form : SOLUTION/DROPS;OPHTHALMIC
Dosage Strength : 0.003%
Approval Date : 2025-05-28
Application Number : 217370
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
STOCK RECAP #PipelineProspector
ABOUT THIS PAGE
75
PharmaCompass offers a list of Acoltremon API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Acoltremon manufacturer or Acoltremon supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Acoltremon manufacturer or Acoltremon supplier.
PharmaCompass also assists you with knowing the Acoltremon API Price utilized in the formulation of products. Acoltremon API Price is not always fixed or binding as the Acoltremon Price is obtained through a variety of data sources. The Acoltremon Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Acoltremon manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Acoltremon, including repackagers and relabelers. The FDA regulates Acoltremon manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Acoltremon API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Acoltremon supplier is an individual or a company that provides Acoltremon active pharmaceutical ingredient (API) or Acoltremon finished formulations upon request. The Acoltremon suppliers may include Acoltremon API manufacturers, exporters, distributors and traders.
Acoltremon Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Acoltremon GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Acoltremon GMP manufacturer or Acoltremon GMP API supplier for your needs.
A Acoltremon CoA (Certificate of Analysis) is a formal document that attests to Acoltremon's compliance with Acoltremon specifications and serves as a tool for batch-level quality control.
Acoltremon CoA mostly includes findings from lab analyses of a specific batch. For each Acoltremon CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Acoltremon may be tested according to a variety of international standards, such as European Pharmacopoeia (Acoltremon EP), Acoltremon JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Acoltremon USP).
